Clinical trials · Ohio
Chronic Myeloid Leukemia clinical trials in Ohio
We’re tracking 37 recruiting chronic myeloid leukemia studies with a site in Ohio — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Columbus, OhioAges 60 years+ - NCT06930352RecruitingPhase 2
Ziftomenib for newly diagnosed AML with NPM1 or KMT2A changes
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
Columbus, OhioAges 18 years+ - NCT06317649RecruitingPhase 2
Venetoclax with hypomethylating agents for older or unfit adults with FLT3-mutated AML
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
Cleveland, OhioAges 18 years+ - NCT05143996RecruitingPhase 1
First study drug for relapsed AML or MDS
This Phase 1 trial tests CLN-049 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or did not respond to treatment. The goal is to find out how well the drug can work and how safe it is in people with limited options.
Cincinnati, OhioAges 18 years+ - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Cleveland, OhioAges 12 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Columbus, OhioAges 18–59 - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Cincinnati, OhioAges 4 weeks+ - NCT07249346RecruitingPhase 2
Preventing GVHD after stem cell transplant with three drugs
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Columbus, OhioAges 18 years+ - NCT06129734RecruitingPhase 1/Phase 2
Maintenance therapy after stem cell transplant for blood cancers
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your blood cancer from coming back. It is for people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or MDS/AML who have had or will have a stem cell transplant.
Cleveland, OhioAges 18 years+ - NCT06634394RecruitingPhase 1
Study of APVO436 for untreated AML patients
This trial tests a new drug called APVO436 for people with a type of acute myeloid leukemia (AML) that has not been treated before. It is for those who cannot receive strong standard chemotherapy due to age, health problems, or organ function issues.
Canton, OhioAges 18 years+ - NCT07007312RecruitingPhase 3
Ziftomenib plus standard chemo for certain AML patients
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
Columbus, OhioAges 18 years+ - NCT06652438RecruitingPhase 3
Revumenib plus standard drugs for NPM1 or KMT2A AML
This trial tests adding a new targeted drug, revumenib, to two standard AML medicines (azacitidine and venetoclax) for adults with a specific gene change (NPM1 mutation or KMT2A rearrangement) who cannot receive strong chemotherapy. The goal is to see if the combination works better.
Cincinnati, OhioAges 18 years+ - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Cleveland, OhioAges 18–59
Where these studies are running in Ohio
Institutions with a site for the recruiting chronic myeloid leukemia studies listed above.
- The Ohio State University · 7 studies
- Case Western Reserve University · 2 studies
- Cincinnati Children's Hospital Medical Center
- Cleveland Clinic Foundation
- Cleveland Clinic Main Campus
- Gabrail Cancer Center
- Oncology Hematology Care
- University Hospitals Cleveland Medical Center
What taking part in a chronic myeloid leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Chronic Myeloid Leukemia trials in other states
Common questions
- Are there chronic myeloid leukemia clinical trials in Ohio?
- Yes. We're currently tracking 37 recruiting chronic myeloid leukemia studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic myeloid leukemia study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic myeloid leukemia studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.